Group One Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Group One Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Sell	5,400 -28,100	-84%	-$509K	﹤0.01%	4811
2026 Q1	$624K	Buy	33,500 +3,000	+10%	+$49.7K	﹤0.01%	3141
2025 Q4	$402K	Sell	30,500 -92,600	-75%	-$1.09M	﹤0.01%	3735
2025 Q3	$883K	Buy	123,100 +34,800	+39%	+$1.81M	﹤0.01%	3161
2025 Q2	$4.17M	Buy	88,300 +88,000	+29,333%	+$3.58M	0.01%	1467
2025 Q1	$11.7K	Sell	300 -65,400	-100%	-$2.82M	﹤0.01%	6154
2024 Q4	$3.56M	Buy	65,700 +100	+0.2%	+$5.11K	0.01%	1420
2024 Q3	$3.31M	Sell	65,600 -800	-1%	-$37.5K	0.01%	1335
2024 Q2	$2.92M	Sell	66,400 -3,500	-5%	-$148K	0.01%	1159
2024 Q1	$3.51M	Buy	69,900 +47,700	+215%	+$2.59M	0.01%	1074
2023 Q4	$1.34M	Buy	22,200 +3,500	+19%	+$180K	﹤0.01%	2190
2023 Q3	$1.07M	Buy	+18,700	New	+$1.03M	﹤0.01%	2200

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Group One Trading's MLTX Position: Q2 2026 in Review

Group One Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 85% in Q2 2026, selling an estimated $333K and leaving 3,179 shares worth $61.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5234.

Group One Trading first reported a position in MLTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $679K in Q1 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Group One Trading held 3,179 shares of MoonLake Immunotherapeutics worth $61.9K as of Q2 2026.
Group One Trading sold 18,384 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $333K.
MoonLake Immunotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5234 holding.
Group One Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 7 quarters since.
Group One Trading's MoonLake Immunotherapeutics position peaked at $679K in Q1 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.